ArticleHereditas2026
Identification and external validation of a prognostic signature based on myeloid-derived suppressor cell-related lncRNAs for hepatocellular carcinoma.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) outcomes remain suboptimal. Myeloid-derived suppressor cells (MDSCs) exhibit notable immunosuppressive and pro-tumorigenic properties. However, the relationship with HCC remains insufficiently explored.
methodsUsing TCGA data, we developed an MDSC-associated lncRNA prognostic model and a clinical nomogram. To explore the model’s mechanistic basis and clinical significance, enrichment analysis, tumor mutation burden (TMB) analysis, tumor microenvironment (TME) evaluation, immunotherapy response prediction, and drug sensitivity assessment were performed. RT-qPCR was utilized to confirm lncRNA expression.
resultsA 7-lncRNA prognostic signature was established. High-risk patients exhibited significantly worse survival (p < 0.001). The nomogram demonstrated superior accuracy over models excluding the risk evaluation. Enrichment analysis exposed that metabolic and immune-associated pathways were predominant within low-risk cohort, while cell proliferation and gene expression regulation dominant across the high-risk population. Meanwhile, an increased TMB and a degraded TME appeared in the high-risk population. The drug responsiveness evaluation revealed that sorafenib, axitinib, and others exhibited enhanced effectiveness among the low-risk population. High-risk individuals displayed enhanced reactions to medications like staurosporine, savolitinib, and others.
conclusionsThe prognostic model constructed based on the seven MDSCs-associated lncRNAs showed good application value in assessing prognosis and guiding clinical therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.